Indications for ANAVIP:
Management of patients with North American rattlesnake envenomation.
Adults and Children:
Administer as soon as possible after rattlesnake bite at any signs of envenomation. Give by IV infusion over 60mins. First 10mins, proceed slowly at 25–50mL/hr rate; monitor for any allergic reaction. If no reaction occurs, increase to 250mL/hr rate until complete. Initially: 10 vials. Observe for ≥60mins after completion of infusion; if no response, repeat additional 10 vial doses every hour until initial control achieved. Once initial control achieved, monitor for ≥18hrs; may give additional 4 vial doses as needed if symptoms re-emerge.
Risk of anaphylactic reaction (esp. if allergic to horse protein). Discontinue and treat if anaphylaxis or hypersensitivity reactions occur. Monitor for delayed allergic reactions or serum sickness; treat appropriately if necessary. Obtain CBCs, platelets, PT/PTT, serum fibrinogen levels, and routine serum chemistries prior to initiation and periodically thereafter. Risk of transmitting infectious agents (eg, viruses). Allergy to cresol. Pregnancy. Nursing mothers.
Pruritus, nausea, rash, arthralgia, peripheral edema, myalgia, headache, pain in extremity, vomiting, erythema; hypersensitivity reactions, serum sickness.